All In Biotech

Drug Trial Radar · NCT04027387

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants

Last checked: Nov 19, 2026Latest source record: Oct 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 14, 2019

Primary completion

Aug 18, 2021

Study completion Aug 18, 2021

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
Collaborators
Westat
First posted
Jul 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans. One dose of the study drug is given to each participant, followed by 10 weeks of monitoring for safety and levels of the drug in the blood. The first group of participants will receive the lowest dose (400 mg). If no safety concerns are seen, the next group will begin at a higher dose (800 mg). If no safety concerns are seen in the second group, the third group will begin at the highest dose in this study (1600 mg).

Conditions

  • HIV-1-infection

Interventions

  • TMB-365Biological

    An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of a single 400mg dose of TMB-365Time frame: 10 weeks
  2. Safety of a single 800mg dose of TMB-365Time frame: 10 weeks
  3. Safety of a single 1600mg dose of TMB-365Time frame: 10 weeks
  4. Pharmacokinetics of a single 400mg dose of TMB-365Time frame: 4 weeks
  5. Pharmacokinetics of a single 800mg dose of TMB-365Time frame: 4 weeks
  6. Pharmacokinetics of a single 1600mg dose of TMB-365Time frame: 4 weeks

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Quest Clinical Research

    San Francisco, California

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • University of Mississippi Medical Center Division of Infectious Diseases

    Jackson, Mississippi

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Clinical Research PR, Inc

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.